The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Real world ibrutinib efficacy for Waldenström’s macroglobulinemia
Jithma Prasad Abeykoon, MD, PhD, of the Mayo Clinic, Rochester, MN, discusses a study investigating Waldenström’s macroglobulinemia patients that were treated with ibrutinib outside of the clinical trial setting. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Abeykoon explains how the study was conducted to evaluate the real world efficacy of ibrutinib. The high overall response rate was very similar to that seen in the clinical trial setting, as were the frequency and type of adverse effects witnessed.
